Feasibility Study to Evaluate the Hybrid-Logic Closed Loop System in Type 1 Diabetes

NCT ID: NCT02692547

Last Updated: 2018-01-19

Basic Information

• Recruitment Status: WITHDRAWN
• Clinical Phase: NA
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-02-29
• Study Completion Date: 2016-02-29

Brief Summary

The purpose of this study is to collect data on the feasibility of the HLCL system in a camp setting.

Detailed Description

This study is a single-arm, single-center, in clinic Investigation in subjects with type 1 diabetes on insulin pump therapy.

Run-in Period A total of up 10 subjects will be enrolled (age 18-25). A minimum of 6 days run-in period with the 640G (sensor augmented pump) will be used to collect sensors and insulin data and to allow the subject to become familiar.

Study Period - Camp Following the run-in period subjects will participate in a 5 day, 4 night study period in an camp setting during which the CL feature will be studied.

Subjects will receive 3 meals each day, one night they receive a high fat dinner, one morning they will receive breakfast high in carbohydrates.

Subjects will be asked to exercise for up to 60 minutes on one day during their study period.

Subjects will be asked to take a minimum of 5 fingersticks a day (before each meal, morning and before bedtime)

Conditions

Type 1 Diabetes

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Hybrid-logic closed loop system

All patients get to wear the pump. only 1 arm. There is no comparator in this study, as all patients wear the pump.

Group Type: OTHER

Hybrid-logic closed loop system

Intervention Type: DEVICE

All patients get to wear the pump

Interventions

Hybrid-logic closed loop system

All patients get to wear the pump

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

1. Diabetes duration > 1 year since diagnosis

2. Sensor augmented Pump for at least 6 months

3. Age 18-25

4. A1C <10.0 at time of screening visit

5. Willing to follow study instructions

6. Willing to perform ≥ 5 finger stick blood glucose measurements daily

7. Willing to perform required sensor calibrations

8. Patient capable of reading and understand instructions in English

Exclusion Criteria

1. Subject is unable to tolerate tape adhesive in the area of sensor placement

2. Subject has any unresolved adverse skin condition in the area of sensor or device placement (e.g., psoriasis, rash, Staphylococcus infection)

3. Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks

4. Subject has a positive pregnancy screening test

5. Subject is female, sexually active without the use of contraception, and plans/able to become pregnant during the course of the study and is not using an acceptable method of contraception

6. Subject has had a hypoglycemic seizure within the past 6 months prior to screening visit

7. Subject has had hypoglycemia resulting in loss of consciousness within the past 6 months prior to screening visit

8. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months prior to screening visit

9. Subject has a history of a seizure disorder

10. Subject has central nervous system or cardiac disorder resulting in syncope

11. Subject has a history of myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack (TIA), cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm disturbances or thromboembolic disease

12. Subjects with hematocrit lower than the normal reference range per POC or local lab testing

13. Subjects with a history or findings on screening electrocardiogram (EKG) of any cardiac arrhythmia, including atrial arrhythmias

14. Subjects with a history of adrenal insufficiency

15. Subjects with history of migraines that have occurred at least 2 times in the last 3 months prior to enrollment

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Medtronic Diabetes

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Moshe Philip, MD

Role: PRINCIPAL_INVESTIGATOR

National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel

Other Identifiers

CEP312

Identifier Type: -

Identifier Source: org_study_id